%PDF-1.4
%
82 0 obj
<>
endobj
79 0 obj
<>
endobj
134 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-29T18:21:25Z
2024-03-28T11:33:05-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T11:33:05-07:00
application/pdf
Heather
2002-897.sept
uuid:8d36218b-1dd2-11b2-0a00-9408278d5b00
uuid:8d36218d-1dd2-11b2-0a00-1e0000000000
endstream
endobj
68 0 obj
<>
endobj
69 0 obj
<>
endobj
83 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 56 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 58 0 R/Type/Page>>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 60 0 R/Type/Page>>
endobj
38 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 62 0 R/Type/Page>>
endobj
156 0 obj
[160 0 R]
endobj
157 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(Rheumatology 1990 criteria for the classification of )17.7 (W)79.9 (egener)-37 (\325)55.1 (s)]TJ
0 -1.25 TD
[(granulomatosis. )54.8 (Arthritis Rheum 1990;33:1)36.8 (101-7.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Hof)17.7 (fman GS, Kerr GS, Leavitt R)54.8 (Y)128.9 (, et al. )17.7 (W)79.9 (egener granulomatosis:)]TJ
1.675 -1.25 Td
[(an analysis of 158 patients. )54.8 (Ann Intern Med 1992;1)36.8 (16:488-98.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Noritake DT)73.9 (, )17.7 (W)79.9 (einer SR, Bassett L)73.9 (W)91.9 (, Paulus HE, )17.7 (W)79.9 (eisbart R.)]TJ
1.675 -1.25 Td
[(Rheumatic manifestations of )17.7 (W)79.9 (egener)-37 (\325)55.1 (s granulomatosis. )]TJ
T*
(J Rheumatol 1987;14:949-51.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Jacobs RP)110.7 (, Moore M, Brower )54.8 (A. )17.7 (W)79.9 (egener)-37 (\325)55.1 (s granulomatosis)]TJ
1.675 -1.25 Td
[(presenting with erosive arthritis. )54.8 (Arthritis Rheum 1987;30:943-6.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Schnabel )54.8 (A, Reuter M, Csernok E, Richter C, Gross )17.7 (WL.)]TJ
1.675 -1.25 Td
(Subclinical alveolar bleeding in pulmonary vasculitides: correlation)Tj
T*
[(with indices of disease activity)64.8 (. Eur Resp J 1999;14:1)36.8 (18-24.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (van der )17.7 (W)79.9 (oude FJ, Rasmussen N, Lobatto S, et al. )54.8 (Autoantibodies)]TJ
2.175 -1.25 Td
(against neutrophils and monocytes: tool for diagnosis and marker)Tj
T*
[(of disease activity in )17.7 (W)79.9 (egener)-37 (\325)55.1 (s granulomatosis. Lancet)]TJ
0 Tc 0 Tw T*
(1985;1:425-9.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Gross )17.7 (WL, Ludemann G, Kiefer G, Lehmann H. )54.8 (Anticytoplasmic)]TJ
2.1381 -1.25 Td
[(antibodies in )17.7 (W)79.9 (egener)-37 (\325)55.1 (s granulomatosis [letter]. Lancet 1986;1:806.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Schultz DR, )17.7 (T)69.9 (ozman EC. )54.8 (Antineutrophil cytoplasmic antibodies:)]TJ
2.175 -1.25 Td
[(major autoantigens, pathophysiology)64.8 (, and disease associations.)]TJ
T*
[(Semin )54.8 (Arthritis Rheum 1995;25:143-59.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Hauschild S, Schmitt )17.7 (WH, Csernok E, Flesch BK, Rautmann )54.8 (A,)]TJ
2.175 -1.25 Td
[(Gross )17.7 (WL. )54.8 (ANCA)-220.2 (in systemic vasculitides, collagen vascular)]TJ
T*
(diseases, rheumatic disorders and inflammatory bowel diseases.)Tj
0 Tc T*
(Adv Exp Med Biol 1993;336:245-51.)Tj
-0.00011 Tc 30.825 33.75 Td
[(14.)-875.1 (Hewins P)110.7 (,)-0.1 ( )17.7 (T)69.9 (ervaert JW)91.7 (, Savage CO, Kallenber)17.7 (g CG. Is )17.7 (W)79.9 (egener)-37 (\325)55.1 (s)]TJ
2.175 -1.25 Td
(granulomatosis an autoimmune disease? Curr Opin Rheumatol)Tj
0 Tc 0 Tw T*
(2000;12:3-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Galperin C, Hof)17.7 (fman GS. )54.8 (Antineutrophil cytoplasmic antibodies in)]TJ
2.175 -1.25 Td
[(W)79.9 (egener)-37 (\325)55.1 (s granulomatosis and other diseases: clinical issues. Cleve)]TJ
0 Tc T*
(Clin J Med 1994;61:416-27.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Locht H, Skogh )17.7 (T)74 (,)-0.1 ( )17.7 (W)39.8 (iik )54.8 (A. Characterisation of autoantibodies to)]TJ
2.175 -1.25 Td
(neutrophil granule constituents among patients with reactive)Tj
T*
[(arthritis, rheumatoid arthritis, and ulcerative colitis. )54.8 (Ann Rheum)]TJ
0 Tc T*
(Dis 2000;59:898-903.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (V)59.8 (ittecoq O, Jouen-Beades F)79.7 (, Krzanowska K, et al. Prospective )]TJ
2.175 -1.25 Td
(evaluation of the frequency and clinical significance of )Tj
T*
(antineutrophil cytoplasmic and anticardiolipin antibodies in)Tj
T*
(community cases of patients with rheumatoid arthritis.)Tj
T*
(Rheumatology 2000;39:481-9.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Bosch X, Llena J, Collado )54.8 (A, et al. Occurrence of antineutrophil)]TJ
2.175 -1.25 Td
(cytoplasmic and antineutrophil \(peri\)nuclear antibodies in )Tj
T*
(rheumatoid arthritis. J Rheumatol 1995;22:2038-45.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Rother E, Schochat )17.7 (T)74 (, Peter HH. )54.8 (Antineutrophil cytoplasmic )]TJ
2.175 -1.25 Td
[(antibodies \(ANCA\) in rheumatoid arthritis: a prospective study)64.8 (.)]TJ
T*
(Rheumatol Int 1996;15:231-7.)Tj
-0.0298 Tw -2.175 -1.25 Td
[(20.)-875.1 (Cho )-54.9 (C, Asuncion A, )-37.1 (T)69.9 (atum AH. )-54.8 (False-positive )-54.8 (antineutrophil )]TJ
0.02499 Tw 2.175 -1.25 Td
[(cytoplasmic antibody in asper)17.7 (gillosis with oxalosis. )54.8 (Arch Pathol)]TJ
T*
[(Lab Med 1995;1)36.8 (19:558-61.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Douglas, et al: WG)-250.1 (and RA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2069)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
62 0 obj
<>stream
8;Z\5!Kr'h#iu"-j?'ar]55n`]o:gl?.mfY0m%sUTR.mQa'c>]gM1G(/>>b,XhVq93r_3.R8.ApV\/6,er8g^.L%YB
>GUgl,M\dt0uikErl)3s@J(>_42obOLZD9BcQ\*XoW4>q8ktgtVAE^mg[6%MpESKh
1lYprP<%u!oLX-pCFi0LAsq8i?&2'"-/MXih<%7>)ptU";
DiY,e)f1[l$-r1S%Fuu/[gR$9B[0Wmck7-0e^drUagq>L]ST$#O[p`1M*rPMphJI-
E=9kpj'C?O5ApcW5+W/JJ)`BdWRp**~>
endstream
endobj
66 0 obj
[/Indexed/DeviceRGB 255 65 0 R]
endobj
65 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
90 0 obj
<>
endobj
85 0 obj
<>
endobj
121 0 obj
<>
endobj
139 0 obj
<>
endobj
86 0 obj
<>
endobj
113 0 obj
<>stream
HU{PSg7\<."AZQيVkQ"H(!@ !!2 bGAZuEem.3Ucg7gs;31'GMEB钭Ѿwc|pf6%N1q.E.y'"/_8o3kwF8U|2?
4E()Y&XcU]WUDIPS! R}4IFL'JB0#ӑ}?@$dBq|Ad D*)҄͂ĥ''HEPjߟK>;\bqO0[A`Bakba qe$BNߑ؋}O8&ʛ;Osv6NaM>ԏ]]j]Ƨm]=5}K3Vt-wtr'Wi#ڪU/alX~Yx; /
h唙mfQ.А#ܕ|(NBlIHy%[9C+a=zcC |_*:q|/GD%#˨,ӕ5gߩ*j8e rpQh~L7455d
!SEٺRu+ȭP/:- Y!R4ʊTEd=aɆ^5Z_FM[``
q/j5LZk|YmғɕRQ$x%D>fM+vMҏ
Bp^\ sm`Q%7(|Fųԛ6oPVqQZVTt:tL
Pݶ=ʝ["Z\ko\{w_'T'^H7vԞcBhMAݛ:vz-D?hdWBi+- >>a {i\ k4Vá "K`*1,O gFا1;iMrȜQ;+6]*^XZ~K7Xwwjy+kN6wt()T`!s`G
WTmo:yLܣ9$[8i4CE?6k'p/mEZAƁm0=y.=颹L;50xkfϰj/EFgوHGs
+1#Z)+ nGU,T+j*xqb6}Cs`B5rlo!o$/Y=">qt*P}]!gC`zB2L0^Vh`Xs49芜hQQI3L
ojE`ԠBb[RhVTO_Nw]FMeXh&ϷMd
Q(6M$g&L=j]MCsvVW^P'l
n2KyGqUj#6ުu/=1<`l8tBRۂ0-Nן3VÅYmKǐ+oeUh-XT